Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus Gehring

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Der Nervenarzt|January 16, 2023
[Erratum to: Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis]Gudrun Goßrau, Stefanie Förderreuther, Ruth Ruscheweyh, et al.
Der Nervenarzt|October 26, 2022
[Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis]Gudrun Goßrau, Stefanie Förderreuther, Ruth Ruscheweyh, et al.
Schmerz (Berlin, Germany)|October 26, 2022
[Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis]Gudrun Goßrau, Stefanie Förderreuther, Ruth Ruscheweyh, et al.
Neurological Research and Practice|April 28, 2026
Protocol of the interdisciplinary and intersectoral randomized controlled trial in Parkinson patients in a specialized network in Germany: the INSPIRE TrialSusanne A Schneider, Sandra Paryjas, Franziska Beyer, et al.
Der Nervenarzt|July 23, 2021
[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Therapeutic Advances in Neurological Disorders|August 23, 2021
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Der Nervenarzt|January 16, 2023
[Erratum to: Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis]Gudrun Goßrau, Stefanie Förderreuther, Ruth Ruscheweyh, et al.
Der Nervenarzt|October 26, 2022
[Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis]Gudrun Goßrau, Stefanie Förderreuther, Ruth Ruscheweyh, et al.
Schmerz (Berlin, Germany)|October 26, 2022
[Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis]Gudrun Goßrau, Stefanie Förderreuther, Ruth Ruscheweyh, et al.
Neurological Research and Practice|April 28, 2026
Protocol of the interdisciplinary and intersectoral randomized controlled trial in Parkinson patients in a specialized network in Germany: the INSPIRE TrialSusanne A Schneider, Sandra Paryjas, Franziska Beyer, et al.
Der Nervenarzt|July 23, 2021
[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Therapeutic Advances in Neurological Disorders|August 23, 2021
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Pageof 2